Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon Makes A $130 Mil. Bet On Mesoblast's Stem Cell Technology

This article was originally published in The Pink Sheet Daily

Executive Summary

The U.S. specialty pharma continues its multi-year effort to expand into biologics by licensing in the Australian biotech's adult stem cell technology for cardiovascular, oncology, and neurodegenerative indications.

You may also be interested in...



Valeant's Bid For Cephalon: Will Opportunism Trump Innovation?

Valeant Pharmaceutical International Inc.'s hostile bid for Cephalon Inc. has all the earmarks of a pharma battle of our times: it pits an R&D-adverse, opportunistic company against a specialty pharma company that is increasingly betting on mid-to-long term innovation.

Valeant's Bid For Cephalon: Will Opportunism Trump Innovation?

Valeant Pharmaceutical International Inc.'s hostile bid for Cephalon Inc. has all the earmarks of a pharma battle of our times: it pits an R&D-adverse, opportunistic company against a specialty pharma company that is increasingly betting on mid-to-long term innovation.

As Cephalon Rejects Valeant Bid, Valeant Officially Goes Hostile

Valeant's offer undervalues Cephalon, its assets and its prospects, and "ignores the proven ability" of its management to maximize opportunities, Cephalon's board says.

Related Content

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel